피부 T세포 림프종(CTCL) : 신규 요법, 미충족 수요 및 TPP 인사이트 보고서(2026년)

Cutaneous T-cell Lymphoma (CTCL) Emerging Therapy and TPP Insights

Thelansis's "Cutaneous T-cell Lymphoma (CTCL) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Cutaneous T-cell Lymphoma (CTCL) Overview

Cutaneous T-cell lymphoma (CTCL) is a rare, skin-based blood cancer in which malignant T-cells infiltrate the skin, typically progressing slowly from patches and plaques toward more advanced tumor or blood-involved stages, with mycosis fungoides as the common form and Sezary syndrome its more aggressive counterpart. Treatment has long followed a stepwise approach, starting with skin-directed therapies such as topical agents, light-based treatment, and localized radiation, then escalating to systemic options, including antibody-based therapies, once disease resists earlier lines. In recent years that systemic toolkit has expanded, with newer antibody and fusion-protein therapies broadening options for patients who previously had few effective choices once disease progressed, particularly in the harder-to-treat Sezary variant. The pipeline behind these approvals remains active for a rare disease, with additional antibody-based and cell-targeted candidates advancing through development, reflecting persistent unmet need in relapsed and refractory patients. For stakeholders, CTCL shows how a rare, chronic malignancy can still sustain a competitive, innovation-driven pipeline.

Key Highlights

• In Germany, incident CTCL cases are expected to increase from 891 in 2025 to 936 by 2035.
• CTCL is a rare non-Hodgkin lymphoma characterized by malignant T-cell infiltration of the skin.
• Patients often experience prolonged disease duration with recurrent symptoms and significant quality-of-life impairment.
• Limited curative options continue to drive demand for novel targeted and immunomodulatory therapies.

Market Overview

• The Germany CTCL market is projected to grow from $73.5M in 2025 to $115.5M by 2035.
• Market expansion is supported by:
• Increased use of targeted therapies and biologics
• Improved disease recognition and specialist referral patterns
• Future growth will depend on innovative therapies for advanced and refractory disease.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Boston Immune Technologies and Therapeutics
• SciTech Development, Inc.
• Chengdu Zenitar Biomedical Technology Co., Ltd.
• Soligenix
• Kymera Therapeutics, Inc.
• Bio-Path Holdings, Inc.
• Prescient Therapeutics, Ltd.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Current challenges
• Unmet needs
• Emerging therapies
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)